DESTINY-Breast03 Phase 3 Study Results
Background
Breast cancer is the second most common cause of brain metastases among solid cancers¹
Growing interest in systemic treatment to improve disease control
HER2 tyrosine-kinase inhibitors in combination with capecitabine yielded clinically relevant activity in BM progressing.
after prior local therapy2,3
Upfront therapy with lapatinib and capecitabine delayed WBRT4
HER2Climb5
☐
Tucatinib + trastuzumab +capecitabine vs. placebo + trastuzumab + capecitabine
☐
Largest population of patients with active BM in a randomized study
Intracranial response rate (active BM): 47.3%
PFS in patients with active BM 9.5 months (95% CI 7.5-11.1)
ESMO guidelines: standard-of-care for active BM if no immediate local therapy is required
Role of antibody drug-conjugates is less well established 6,7
■
DEBBRAH: RR (T-DXd) in progressive BM 44.4% (4/9 pts.)8
1 Weil RJ et al. Am J Pathol 2005;167:913-920.; 2 Lin NU et al. Clin Cancer Res 2009;15:1452-1459.; 3 Freedman RA et al. J Clin Oncol 2019;37:1081-1089.; 4 Bachelot T et al. Lancet
Oncol 2013;14:64-71.; 5 Lin NU et al. J Clin Oncol 2020;38:2610-2619.; 6 Montemurro F et al. Ann Oncol 2020;31:1350-1358.; 7 Hurvitz S et al. GS3-01; SABCS 2021.; 8 Vaz Batista M et
al. PF4-06; SABCS 2021.
ESMO BC 2022 #165 Mini Oral
Daiichi-Sankyo
51View entire presentation